Challenges and status: Single-use bioreactors for microbial processes

Nowadays single-use bioreactors are fully accepted in the biopharmaceutical industry. Reactors up to 2000L working volume are commonly used. However, these bioreactors are limited in terms of mass-transfer and mixing capabilities and therefore only suited for application in mammalian cell culture. Single-use processing offers many benefits like cost reduction, flexibility, reduction of contamination risks, etc. These benefits apply for both microbial processes as for mammalian processes. Additionally, for the use of marine microorganisms the application of single-use bioreactors (SUB) offers a possibility to circumvent problem of corrosion which occurs in steel bioreactors due to the high chloride ion concentration in the media when the early stage of process development or the need for multi-purpose devices does not allow the investment in process-specific infrastructure. However, marine production processes can demand for high gas mass transfer rates, e.g. in the case of Crypthecodinium cohnii, a heterotrophic algae applied for the production of the polyunsatured fatty acid docosahexaenoic acid. C. cohnii cells are highly sensitive to shear-forces. In general, unfavorable cultivation conditions lead to a high batch-to-batch variation, and thus to a random process development and optimization. In this paper we describe experience of the use of different single use bioreactors for the high cell density cultivation of C. cohnii and other microorganisms. Specific parameters we looked at were the gas transfer efficiency as an important parameter for high cell and product yields as well as the opportunity for expansion of the culture over a wide volume range. Among various SUBs, which were tested, only the 2-D wave-mixed CELL-tainer® showed a high oxygen mass transfer at comparably low shear forces, and hence provided a very vital culture.1, 2 In order to broaden the range of the working volume, expansion channel blocks were applied, which allow performing cultivations from 150 ml to 20 L without reinocculation. However, the scalability of a wave-mixed system is challenging due to the restricted knowledge of classical engineering parameters. Therefore, the physiologic and morphologic constitution of the cells was considered to prove the suitability of the SUBs at scales from the mL to the 120 L range. Therefore a novel on-line photo-optical instrument (SOPAT) for the analysis of cell shapes, and lipid droplet accumulation was applied. It allowed a direct insight into the stage of growth, population homogeneity, and fatty acid production. Although it is hardly feasible to maintain identical cultivation conditions from the µL to the m³ scale, the combination of engineering parameters and process analytical tools led to the overall achievement of suitable cultivation conditions. The presented on-line method in relation to the developmental strategy over different scales is relevant for the development of plant and other cell culture processes, while contributing to reduced development times and costs

A Photolyase-Like Protein from Agrobacterium tumefaciens with an Iron-Sulfur Cluster

Photolyases and cryptochromes are evolutionarily related flavoproteins with distinct functions. While photolyases can repair UV-induced DNA lesions in a light-dependent manner, cryptochromes regulate growth, development and the circadian clock in plants and animals. Here we report about two photolyase-related proteins, named PhrA and PhrB, found in the phytopathogen Agrobacterium tumefaciens. PhrA belongs to the class III cyclobutane pyrimidine dimer (CPD) photolyases, the sister class of plant cryptochromes, while PhrB belongs to a new class represented in at least 350 bacterial organisms. Both proteins contain flavin adenine dinucleotide (FAD) as a primary catalytic cofactor, which is photoreduceable by blue light. Spectral analysis of PhrA confirmed the presence of 5,10-methenyltetrahydrofolate (MTHF) as antenna cofactor. PhrB comprises also an additional chromophore, absorbing in the short wavelength region but its spectrum is distinct from known antenna cofactors in other photolyases. Homology modeling suggests that PhrB contains an Fe-S cluster as cofactor which was confirmed by elemental analysis and EPR spectroscopy. According to protein sequence alignments the classical tryptophan photoreduction pathway is present in PhrA but absent in PhrB. Although PhrB is clearly distinguished from other photolyases including PhrA it is, like PhrA, required for in vivo photoreactivation. Moreover, PhrA can repair UV-induced DNA lesions in vitro. Thus, A. tumefaciens contains two photolyase homologs of which PhrB represents the first member of the cryptochrome/photolyase family (CPF) that contains an iron-sulfur cluster

Interactions among the A and T Units of an ECF-Type Biotin Transporter Analyzed by Site-Specific Crosslinking

Energy-coupling factor (ECF) transporters are a huge group of micronutrient importers in prokaryotes. They are composed of a substrate-specific transmembrane protein (S component) and a module consisting of a moderately conserved transmembrane protein (T component) and two ABC ATPase domains (A components). Modules of A and T units may be dedicated to a specific S component or shared by many different S units in an organism. The mode of subunit interactions in ECF transporters is largely unknown. BioMNY, the focus of the present study, is a biotin transporter with a dedicated AT module. It consists of the S unit BioY, the A unit BioM and the T unit BioN. Like all T units, BioN contains two three-amino-acid signatures with a central Arg residue in a cytoplasmic helical region. Our previous work had demonstrated a central role of the two motifs in T units for stability and function of BioMNY and other ECF transporters. Here we show by site-specific crosslinking of pairs of mono-cysteine variants that the Ala-Arg-Ser and Ala-Arg-Gly signatures in BioN are coupling sites to the BioM ATPases. Analysis of 64 BioN-BioM pairs uncovered interactions of both signatures predominantly with a segment of ∼13 amino acid residues C-terminal of the Q loop of BioM. Our results further demonstrate that portions of all BioN variants with single Cys residues in the two signatures are crosslinked to homodimers. This finding may point to a dimeric architecture of the T unit in BioMNY complexes

A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial

Background Cough can be a debilitating symptom of idiopathic pulmonary fibrosis (IPF) and is difficult to treat. PA101 is a novel formulation of sodium cromoglicate delivered via a high-efficiency eFlow nebuliser that achieves significantly higher drug deposition in the lung compared with the existing formulations. We aimed to test the efficacy and safety of inhaled PA101 in patients with IPF and chronic cough and, to explore the antitussive mechanism of PA101, patients with chronic idiopathic cough (CIC) were also studied. Methods This pilot, proof-of-concept study consisted of a randomised, double-blind, placebo-controlled trial in patients with IPF and chronic cough and a parallel study of similar design in patients with CIC. Participants with IPF and chronic cough recruited from seven centres in the UK and the Netherlands were randomly assigned (1:1, using a computer-generated randomisation schedule) by site staff to receive PA101 (40 mg) or matching placebo three times a day via oral inhalation for 2 weeks, followed by a 2 week washout, and then crossed over to the other arm. Study participants, investigators, study staff, and the sponsor were masked to group assignment until all participants had completed the study. The primary efficacy endpoint was change from baseline in objective daytime cough frequency (from 24 h acoustic recording, Leicester Cough Monitor). The primary efficacy analysis included all participants who received at least one dose of study drug and had at least one post-baseline efficacy measurement. Safety analysis included all those who took at least one dose of study drug. In the second cohort, participants with CIC were randomly assigned in a study across four centres with similar design and endpoints. The study was registered with ClinicalTrials.gov (NCT02412020) and the EU Clinical Trials Register (EudraCT Number 2014-004025-40) and both cohorts are closed to new participants. Findings Between Feb 13, 2015, and Feb 2, 2016, 24 participants with IPF were randomly assigned to treatment groups. 28 participants with CIC were enrolled during the same period and 27 received study treatment. In patients with IPF, PA101 reduced daytime cough frequency by 31·1% at day 14 compared with placebo; daytime cough frequency decreased from a mean 55 (SD 55) coughs per h at baseline to 39 (29) coughs per h at day 14 following treatment with PA101, versus 51 (37) coughs per h at baseline to 52 (40) cough per h following placebo treatment (ratio of least-squares [LS] means 0·67, 95% CI 0·48–0·94, p=0·0241). By contrast, no treatment benefit for PA101 was observed in the CIC cohort; mean reduction of daytime cough frequency at day 14 for PA101 adjusted for placebo was 6·2% (ratio of LS means 1·27, 0·78–2·06, p=0·31). PA101 was well tolerated in both cohorts. The incidence of adverse events was similar between PA101 and placebo treatments, most adverse events were mild in severity, and no severe adverse events or serious adverse events were reported. Interpretation This study suggests that the mechanism of cough in IPF might be disease specific. Inhaled PA101 could be a treatment option for chronic cough in patients with IPF and warrants further investigation

Cohort Profile: Post-hospitalisation COVID-19 study (PHOSP-COVID)

PHOSP-COVID is a national UK multi-centre cohort study of patients who were hospitalised for COVID-19 and subsequently discharged.PHOSP-COVID was established to investigate the medium- and long-term sequelae of severe COVID-19 requiring hospitalisation, understand the underlying mechanisms of these sequelae, evaluate the medium- and long-term effects of COVID-19 treatments, and to serve as a platform to enable future studies, including clinical trials.Data collected covered a wide range of physical measures, biological samples, and Patient Reported Outcome Measures (PROMs).Participants could join the cohort either in Tier 1 only with remote data collection using hospital records, a PROMs app and postal saliva sample for DNA, or in Tier 2 where they were invited to attend two specific research visits for further data collection and biological research sampling. These research visits occurred at five (range 2-7) months and 12 (range 10-14) months post-discharge. Participants could also participate in specific nested studies (Tier 3) at selected sites.All participants were asked to consent to further follow-up for 25 years via linkage to their electronic healthcare records and to be re-contacted for further research.In total, 7935 participants were recruited from 83 UK sites: 5238 to Tier 1 and 2697 to Tier 2, between August 2020 and March 2022.Cohort data are held in a Trusted Research Environment and samples stored in a central biobank. Data and samples can be accessed upon request and subject to approvals

Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study

Introduction: The multiorgan impact of moderate to severe coronavirus infections in the post-acute phase is still poorly understood. We aimed to evaluate the excess burden of multiorgan abnormalities after hospitalisation with COVID-19, evaluate their determinants, and explore associations with patient-related outcome measures. Methods: In a prospective, UK-wide, multicentre MRI follow-up study (C-MORE), adults (aged ≥18 years) discharged from hospital following COVID-19 who were included in Tier 2 of the Post-hospitalisation COVID-19 study (PHOSP-COVID) and contemporary controls with no evidence of previous COVID-19 (SARS-CoV-2 nucleocapsid antibody negative) underwent multiorgan MRI (lungs, heart, brain, liver, and kidneys) with quantitative and qualitative assessment of images and clinical adjudication when relevant. Individuals with end-stage renal failure or contraindications to MRI were excluded. Participants also underwent detailed recording of symptoms, and physiological and biochemical tests. The primary outcome was the excess burden of multiorgan abnormalities (two or more organs) relative to controls, with further adjustments for potential confounders. The C-MORE study is ongoing and is registered with ClinicalTrials.gov, NCT04510025. Findings: Of 2710 participants in Tier 2 of PHOSP-COVID, 531 were recruited across 13 UK-wide C-MORE sites. After exclusions, 259 C-MORE patients (mean age 57 years [SD 12]; 158 [61%] male and 101 [39%] female) who were discharged from hospital with PCR-confirmed or clinically diagnosed COVID-19 between March 1, 2020, and Nov 1, 2021, and 52 non-COVID-19 controls from the community (mean age 49 years [SD 14]; 30 [58%] male and 22 [42%] female) were included in the analysis. Patients were assessed at a median of 5·0 months (IQR 4·2–6·3) after hospital discharge. Compared with non-COVID-19 controls, patients were older, living with more obesity, and had more comorbidities. Multiorgan abnormalities on MRI were more frequent in patients than in controls (157 [61%] of 259 vs 14 [27%] of 52; p<0·0001) and independently associated with COVID-19 status (odds ratio [OR] 2·9 [95% CI 1·5–5·8]; padjusted=0·0023) after adjusting for relevant confounders. Compared with controls, patients were more likely to have MRI evidence of lung abnormalities (p=0·0001; parenchymal abnormalities), brain abnormalities (p<0·0001; more white matter hyperintensities and regional brain volume reduction), and kidney abnormalities (p=0·014; lower medullary T1 and loss of corticomedullary differentiation), whereas cardiac and liver MRI abnormalities were similar between patients and controls. Patients with multiorgan abnormalities were older (difference in mean age 7 years [95% CI 4–10]; mean age of 59·8 years [SD 11·7] with multiorgan abnormalities vs mean age of 52·8 years [11·9] without multiorgan abnormalities; p<0·0001), more likely to have three or more comorbidities (OR 2·47 [1·32–4·82]; padjusted=0·0059), and more likely to have a more severe acute infection (acute CRP >5mg/L, OR 3·55 [1·23–11·88]; padjusted=0·025) than those without multiorgan abnormalities. Presence of lung MRI abnormalities was associated with a two-fold higher risk of chest tightness, and multiorgan MRI abnormalities were associated with severe and very severe persistent physical and mental health impairment (PHOSP-COVID symptom clusters) after hospitalisation. Interpretation: After hospitalisation for COVID-19, people are at risk of multiorgan abnormalities in the medium term. Our findings emphasise the need for proactive multidisciplinary care pathways, with the potential for imaging to guide surveillance frequency and therapeutic stratification

Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study

Background The impact of COVID-19 on physical and mental health and employment after hospitalisation with acute disease is not well understood. The aim of this study was to determine the effects of COVID-19-related hospitalisation on health and employment, to identify factors associated with recovery, and to describe recovery phenotypes. Methods The Post-hospitalisation COVID-19 study (PHOSP-COVID) is a multicentre, long-term follow-up study of adults (aged ≥18 years) discharged from hospital in the UK with a clinical diagnosis of COVID-19, involving an assessment between 2 and 7 months after discharge, including detailed recording of symptoms, and physiological and biochemical testing. Multivariable logistic regression was done for the primary outcome of patient-perceived recovery, with age, sex, ethnicity, body-mass index, comorbidities, and severity of acute illness as covariates. A post-hoc cluster analysis of outcomes for breathlessness, fatigue, mental health, cognitive impairment, and physical performance was done using the clustering large applications k-medoids approach. The study is registered on the ISRCTN Registry (ISRCTN10980107). Findings We report findings for 1077 patients discharged from hospital between March 5 and Nov 30, 2020, who underwent assessment at a median of 5·9 months (IQR 4·9–6·5) after discharge. Participants had a mean age of 58 years (SD 13); 384 (36%) were female, 710 (69%) were of white ethnicity, 288 (27%) had received mechanical ventilation, and 540 (50%) had at least two comorbidities. At follow-up, only 239 (29%) of 830 participants felt fully recovered, 158 (20%) of 806 had a new disability (assessed by the Washington Group Short Set on Functioning), and 124 (19%) of 641 experienced a health-related change in occupation. Factors associated with not recovering were female sex, middle age (40–59 years), two or more comorbidities, and more severe acute illness. The magnitude of the persistent health burden was substantial but only weakly associated with the severity of acute illness. Four clusters were identified with different severities of mental and physical health impairment (n=767): very severe (131 patients, 17%), severe (159, 21%), moderate along with cognitive impairment (127, 17%), and mild (350, 46%). Of the outcomes used in the cluster analysis, all were closely related except for cognitive impairment. Three (3%) of 113 patients in the very severe cluster, nine (7%) of 129 in the severe cluster, 36 (36%) of 99 in the moderate cluster, and 114 (43%) of 267 in the mild cluster reported feeling fully recovered. Persistently elevated serum C-reactive protein was positively associated with cluster severity. Interpretation We identified factors related to not recovering after hospital admission with COVID-19 at 6 months after discharge (eg, female sex, middle age, two or more comorbidities, and more acute severe illness), and four different recovery phenotypes. The severity of physical and mental health impairments were closely related, whereas cognitive health impairments were independent. In clinical care, a proactive approach is needed across the acute severity spectrum, with interdisciplinary working, wide access to COVID-19 holistic clinical services, and the potential to stratify care. Funding UK Research and Innovation and National Institute for Health Research

Entwurf einer Bildungsperspektive im Nachhaltigkeitszeitalter : kritischer Rollendiskurs der Bildung für eine nachhaltige Entwicklung in der Lebenswirklichkeit von Erwachsenen

Die Herausforderungen des Klimawandels sind für unsere Gesellschaft spürbar geworden. Speziell die Umsetzung von nicht überfordernder Bewusstseinsbildung in der Lebens-wirklichkeit von einzelnen Erwachsenen, stellt die Quintessenz dieser Arbeit dar. Besondere Aufmerksamkeit erhalten daher, im ganzheitlichen Kontakt zur Nachhaltigkeit, die sozialwissenschaftlichen Disziplinen, die sich der psychosozialen, inneren Zusammenhänge zum Thema Nachhaltigkeit annehmen. Die naturwissenschaftlichen Disziplinen lieferten in den letzten vierzig Jahren die passenden Fakten eventueller zukünftiger Herausforderungen jedoch die Sozialwissenschaften haben heute und in zukünftigen Zeiten den Auftrag, die gesellschaftliche Transformation und die damit einhergehenden Veränderungen auf ihre Vermittelbarkeitsmöglichkeiten zu analysieren und Menschen in ihren Lebenswirklichkeiten bei der Umsetzung zu stützen. Sinnvoll ist es daher transparent und allgegenwärtig in allen Bereichen der Wissenschaft zu forschen und in allen Bereichen der Bildung zu vermitteln, „was wir tun können“ um die große Herausforderung des neuen Jahrtausends für die Wissenschaft: „den Schutz der Umwelt“, zu gewährleisten. Das erforschen der einzelnen Lebenswirklichkeiten durch kurze Memos von verschiedensten Menschen, liefern zwar keine Beantwortung der Forschungsfrage: Kann (Weiter)Bildung unter Berücksichtigung von vorhandenen Qualitätsnarrationen in alternativen Handlungsräumen die Teilhabe an einer nachhaltigen Entwicklung fördern?, aber die Memos sind spontane Impression zum Thema, die einen überwiegend starken Wissenstands, der Gesprächspartnerinnen und Gesprächs-partner, in allen drei erforschten Handlungsräumen, erreichen (Alltagshandlungsraum, Bildungs- und Berufswelt, Mitbestimmungsprozess;). Dies ist ein Indiz dafür, dass wir uns bereits mitten in einem transformativen Lebensakt befinden und der Fokus nun stärker auf das robust machen von Wissen für einzelne Menschen gelenkt werden sollte.The challenges of climate change have become tangible for our society. The quintessence of this work is especially the implementation of not overly demanding awareness in the realities of life about single adults. Therefore, in the holistic contact to sustainability. Special attention is paid to the socio-scientific disciplines that deal with the psycho-social, internal connections to the topic of sustainability. The scientific disciplines have provided the appropriate facts of possible future challenges in the last forty years, but the social sciences today and in future times, have the mission to analyze the social transformation and the accompanying changes on their employability and to support people in their realities in the implementation. It makes sense, therefore, to conduct research in all areas of science in a transparent and ubiquitous manner and to communicate in all areas of education "what we can do" to ensure the great challenge of the new millennium to science: "the protection of the environment". Researching the individual realities of life through short „memos“ from various people does not answer the research question: Can (further)education, taking into account existing quality narratives in alternative action spaces, promote participation in sustainable development?, but the memos are spontaneous impressions on the topic, which reach a predominantly strong level of knowledge about the interlocutors, in all three areas of action explored (three areas: everyday acting space, education and work and co-determination process;). This is an indication that we are already in the midst of a transformative act of life, and the focus should now be more on the „robustness of knowledge“ for individual people.vorgelegt von Olivia Neubauer-SuppanZusammenfassungen in Deutsch und EnglischAbweichender Titel laut Übersetzung des Verfassers/der VerfasserinKarl-Franzens-Universität Graz, Masterarbeit, 2019(VLID)364284